Clinical trial
A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
NCT05807399 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
- Lead sponsor
- Michael Hoelscher
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 14, 2023
- Completion date
- December 30, 2027
- Enrollment
- 390 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
other specified pulmonary tuberculosis, pulmonary tuberculosis